Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.68 |
| ▸ | MAPT | P10636 | 9/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.68 |
| ▸ | NPC1 | O15118 | 7/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428793 | 0.83 | RAB9A (0.96) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL28679988 | 0.83 | LTA4H (0.66) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL3761118 | 0.83 | RAB9A (0.66) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL1774137 | 0.83 | RAB9A (0.58) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL3823252 | 0.83 | RAB9A (0.58) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL2225468 | 0.82 | ALDH1A1 (0.63) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL20504926 | 0.81 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| Bromide SCHEMBL4433292 | 0.81 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL1764592 | 0.81 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL6174249 | 0.81 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501031-B | Oxazolidone derivatives as PR modulators | WYETH (US) | 2012-02-01 | — | — | CN | disclosed |
| US-7652018-B2 | Imidazolidin-2-one derivatives useful as PR modulators | WYETH LLC (US) | 2010-01-26 | — | — | US | disclosed |
| US-7649007-B2 | Oxazolidine derivatives as PR modulators | WYETH LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7618989-B2 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| CN-101501031-A | Oxazolidone derivatives as pr modulators | WYETH CORP (US) | 2009-08-05 | — | — | CN | disclosed |
| US-7538107-B2 | Oxazinan-2-one derivatives useful as PR modulators | WYETH (US) | 2009-05-26 | — | — | US | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045579-A1 | Oxazolidine derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021337-A1 | OXAZINAN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021309-A1 | IMIDAZOLIDIN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021339-A2 | PYRROLIDINE AND RELATED DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021338-A2 | TRICYCLIC OXAZOLIDONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045518-A1 | Oxazinan-2-one derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045518-A1 | Oxazinan-2-one derivatives useful as PR modulators | NPY1R, OXTR, GNRHR | RAB9A 2511/4885MAPT 1146/4885SMN1; SMN2 2791/4885 |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | PKD1, SHBG, NPY4R | RAB9A 2193/4885MAPT 1647/4885SMN1; SMN2 3676/4885 |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | PRLHR, GNRHR, NPY1R | RAB9A 830/4885MAPT 858/4885SMN1; SMN2 3154/4885 |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | MC2R, GNRHR, MC3R | RAB9A 2089/4885MAPT 1702/4885SMN1; SMN2 3186/4885 |
| US-20080045579-A1 | Oxazolidine derivatives as PR modulators | NPY1R, GNRHR, KISS1R | RAB9A 469/4885MAPT 1518/4885SMN1; SMN2 3158/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | RAB9A 1677/4885MAPT 1550/4885SMN1; SMN2 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.